Research programme: oncolytic virus therapies and diagnostics - Oncolys BioPharma

Drug Profile

Research programme: oncolytic virus therapies and diagnostics - Oncolys BioPharma

Alternative Names: hTERTp-Ad5; OBP 405; OBP 502; OBP 702; OBP-1101; OBP-401; OBP-401/1101 ; Telomelysin-RGD; TelomeScan F35; TelomeScan®

Latest Information Update: 01 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Biomedical Innovation; Okayama University
  • Developer Oncolys BioPharma
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Osteosarcoma; Solid tumours

Most Recent Events

  • 24 May 2018 Oncolys BioPharma in-licenses Therm-SB™ virus stability platform technology from Stabilitech Biopharma
  • 21 Apr 2018 Preclinical trials in Osteosarcoma (Combination therapy) in Japan (unspecified route)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Osteosarcoma presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top